Underuse of self-controlled designs in pharmacoepidemiology in electronic healthcare databases: a systematic review |
journalArticle |
2016 |
Gault, N.; Castaneda-Sanabria, J.; Guillo, S.; Foulon, S.; Tubach, F. |
Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status |
journalArticle |
2015 |
Messai, Y.; Gad, S.; Noman, M. Z.; Le Teuff, G.; Couve, S.; Janji, B.; Kammerer, S. F.; Rioux-Leclerc, N.; Hasmim, M.; Ferlicot, S.; Baud, V.; Mejean, A.; Mole, D. R.; Richard, S.; Eggermont, A. M.; Albiges, L.; Mami-Chouaib, F.; Escudier, B.; Chouaib, S. |
Daily versus weekly prostate cancer image-guided radiotherapy: Phase 3 multicenter randomized trial |
journalArticle |
2018 |
de Crevoisier, R.; Bayar, M. A.; Pommier, P.; Muracciole, X.; Pêne, F.; Dudouet, P.; Latorzeff, I.; Beckendorf, V.; Bachaud, J. M.; Laplanche, A.; Supiot, S.; Chauvet, B.; Nguyen, T. D.; Bossi, A.; Créhange, G.; Lagrange, J. L. |
Joint model for left-censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000-05 trial |
journalArticle |
2016 |
Krol, A.; Ferrer, L.; Pignon, J. P.; Proust-Lima, C.; Ducreux, M.; Bouche, O.; Michiels, S.; Rondeau, V. |
C-Reactive Protein Values After Colorectal Resection: Can We Discharge a Patient With a C-Reactive Protein Value >100? A Retrospective Cohort Study |
journalArticle |
2019 |
Benoit, O.; Faron, M.; Margot, N.; Creavin, B.; Debove, C.; Tiret, E.; Parc, Y.; Lefevre, J. H. |
Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial |
journalArticle |
2017 |
Desportes, E.; Wagner, M.; Kamal, M.; Salomon, A. V.; Deniziaut, G.; Pierron, G.; Rouleau, E.; Jouffroy, T.; Le Tourneau, C.; Paoletti, X.; Servois, V. |
Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study |
journalArticle |
2016 |
Lueza, B.; Mauguen, A.; Pignon, J. P.; Rivero-Arias, O.; Bonastre, J.; Group, Mar-Lc Collaborative |
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials |
journalArticle |
2015 |
Dowsett, M.; Forbes, J. F.; Bradley, R.; Ingle, J.; Aihara, T.; Bliss, J.; Boccardo, F.; Coates, A.; Coombes, R. C.; Cuzick, J.; Dubsky, P.; Gnant, M.; Kaufmann, M.; Kilburn, L.; Perrone, F.; Rea, D.; Thürlimann, B.; van de Velde, C.; Pan, H.; Peto, R.; Davies, C.; Gray, R. |
Nail toxicities induced by systemic anticancer treatments |
journalArticle |
2015 |
Robert, C.; Sibaud, V.; Mateus, C.; Verschoore, M.; Charles, C.; Lanoy, E.; Baran, R. |
Chemotherapy for Nasopharyngeal Carcinoma - Current Recommendation and Controversies |
journalArticle |
2015 |
Sze, H.; Blanchard, P.; Ng, W. T.; Pignon, J. P.; Lee, A. W. |
Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma |
journalArticle |
2016 |
Peeler, C. R.; Mirkovic, D.; Titt, U.; Blanchard, P.; Gunther, J. R.; Mahajan, A.; Mohan, R.; Grosshans, D. R. |
Peritoneal Metastases from Colorectal Cancer: Treatment Principles and Perspectives |
journalArticle |
2018 |
Goere, D.; Sourrouille, I.; Gelli, M.; Benhaim, L.; Faron, M.; Honore, C. |
The 5000% case: a glimpse into the financial issue of lung cancer treatment |
journalArticle |
2016 |
Remon, J.; Bonastre, J.; Besse, B. |
Intramuscular administration of alfaxalone for sedation in rabbits |
journalArticle |
2015 |
Huynh, M.; Poumeyrol, S.; Pignon, C.; Le Teuff, G.; Zilberstein, L. |
Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort |
journalArticle |
2016 |
Blanchard, P.; Wong, A. J.; Gunn, G. B.; Garden, A. S.; Mohamed, A. S.; Rosenthal, D. I.; Crutison, J.; Wu, R.; Zhang, X.; Zhu, X. R.; Mohan, R.; Amin, M. V.; Fuller, C. D.; Frank, S. J. |
Systemic inflammatory disorders in patients admitted for aseptic meningitis |
journalArticle |
2018 |
de la Motte, M. B.; Abbas, R.; Jouan, F.; van Gysel, D.; Chauveheid, M. P.; Papo, T.; Sacre, K. |
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials |
journalArticle |
2017 |
Arnold, D.; Lueza, B.; Douillard, J. Y.; Peeters, M.; Lenz, H. J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J. P.; Tabernero, J.; Cervantes, A.; Ciardiello, F. |
Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials |
journalArticle |
2015 |
Faron, M.; Pignon, J. P.; Malka, D.; Bourredjem, A.; Douillard, J. Y.; Adenis, A.; Elias, D.; Bouché, O.; Ducreux, M. |
Readressing the rationale of irradiation in stage I seminoma guidelines: a critical essay |
journalArticle |
2019 |
Berghen, C.; Albersen, M.; Blanchard, P.; Bossi, A.; Briganti, A.; Cozzarini, C.; Decaestecker, K.; Fonteyne, V.; Haustermans, K.; Joniau, S.; Lim Joon, D.; Khoo, V.; Nguyen, P. L.; Ost, P.; Villeirs, G.; Vulsteke, C.; Zietman, A.; De Meerleer, G. |
Innovations for phase I dose-finding designs in pediatric oncology clinical trials |
journalArticle |
2016 |
Doussau, A.; Geoerger, B.; Jimenez, I.; Paoletti, X. |
Radioactive iodine ablation in low-risk thyroid cancer - Authors' reply |
journalArticle |
2018 |
Leboulleux, S.; Borget, I.; Schlumberger, M. |
Enjeux méthodologiques de la médecine de précision en oncologie |
journalArticle |
2017 |
Asselain, B.; Paoletti, X. |
INTRODUCTION OF INNOVATIVE MEDICAL DEVICES AT FRENCH UNIVERSITY HOSPITALS: AN OVERVIEW OF HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT INITIATIVES |
journalArticle |
2015 |
Martelli, N.; Billaux, M.; Borget, I.; Pineau, J.; Prognon, P.; van den Brink, H. |
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease |
journalArticle |
2018 |
Danlos, F. X.; Voisin, A. L.; Dyevre, V.; Michot, J. M.; Routier, E.; Taillade, L.; Champiat, S.; Aspeslagh, S.; Haroche, J.; Albiges, L.; Massard, C.; Girard, N.; Dalle, S.; Besse, B.; Laghouati, S.; Soria, J. C.; Mateus, C.; Robert, C.; Lanoy, E.; Marabelle, A.; Lambotte, O. |
How to Model Survival In Cost-Effectiveness Analysis? Differences Between Markov and Partitioned Survival Analysis Models |
journalArticle |
2015 |
Minacori, R.; Bonastre, J.; Lueza, B.; Marguet, S.; Levy, P. |
Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei |
journalArticle |
2019 |
Benhaim, L.; Faron, M.; Gelli, M.; Sourrouille, I.; Honore, C.; Delhorme, J. B.; Elias, D.; Goere, D. |
Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial |
journalArticle |
2016 |
Loi, S.; Dafni, U.; Karlis, D.; Polydoropoulou, V.; Young, B. M.; Willis, S.; Long, B.; de Azambuja, E.; Sotiriou, C.; Viale, G.; Ruschoff, J.; Piccart, M. J.; Dowsett, M.; Michiels, S.; Leyland-Jones, B. |
A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials |
journalArticle |
2015 |
Doussau, A.; Thiebaut, R.; Geoerger, B.; Schoffski, P.; Floquet, A.; Le Deley, M. C.; Mathoulin-Pelissier, S.; Rizzo, E.; Fumoleau, P.; Le Tourneau, C.; Paoletti, X. |
Designs of drug-combination phase I trials in oncology: a systematic review of the literature |
journalArticle |
2015 |
Riviere, M. K.; Le Tourneau, C.; Paoletti, X.; Dubois, F.; Zohar, S. |
Hypofractionation for prostate cancer: a word of caution |
journalArticle |
2016 |
Bossi, A.; Blanchard, P. |
Reply to V.P. Retel et al, D. Gauchan et al, and C. Rahilly-Tierney et al |
journalArticle |
2015 |
Bonastre, J.; Marguet, S.; Lueza, B.; Michiels, S.; Delaloge, S.; Saghatchian, M. |
Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement |
journalArticle |
2015 |
Stewart, L. A.; Clarke, M.; Rovers, M.; Riley, R. D.; Simmonds, M.; Stewart, G.; Tierney, J. F.; Group, Prisma-Ipd Development |
Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role? |
journalArticle |
2016 |
Ou, D.; Levy, A.; Blanchard, P.; Nguyen, F.; Garberis, I.; Casiraghi, O.; Scoazec, J. Y.; Janot, F.; Temam, S.; Deutsch, E.; Tao, Y. |
Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer |
journalArticle |
2019 |
Kothari, G.; Ost, P.; Cheung, P.; Blanchard, P.; Tree, A. C.; van As, N. J.; Lo, S. S.; Moghanaki, D.; Loblaw, A.; Siva, S. |
Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973) |
journalArticle |
2018 |
Goéré, D.; Pignon, J. P.; Gelli, M.; Elias, D.; Benhaim, L.; Deschamps, F.; Caramella, C.; Boige, V.; Ducreux, M.; de Baere, T.; Malka, D. |
Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma |
journalArticle |
2016 |
Regairaz, M.; Munier, F.; Sartelet, H.; Castaing, M.; Marty, V.; Renauleaud, C.; Doux, C.; Delbe, J.; Courty, J.; Fabre, M.; Ohta, S.; Vielh, P.; Michiels, S.; Valteau-Couanet, D.; Vassal, G. |
Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma |
journalArticle |
2015 |
Hadoux, J.; Malka, D.; Planchard, D.; Scoazec, J. Y.; Caramella, C.; Guigay, J.; Boige, V.; Leboulleux, S.; Burtin, P.; Berdelou, A.; Loriot, Y.; Duvillard, P.; Chougnet, C. N.; Déandréis, D.; Schlumberger, M.; Borget, I.; Ducreux, M.; Baudin, E. |
Looking Beyond the Numbers: Highlighting the Challenges of Population-Based Studies in Cancer Research |
journalArticle |
2016 |
Blanchard, P.; Garden, A. S. |
Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy |
journalArticle |
2017 |
Annede, P.; Seisen, T.; Klotz, C.; Mazeron, R.; Maroun, P.; Petit, C.; Deutsch, E.; Bossi, A.; Haie-Meder, C.; Chargari, C.; Blanchard, P. |
[The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB] |
journalArticle |
2015 |
Ezzalfani, M.; Dugue, A.; Mollevi, C.; Pulido, M.; Bonnetain, F.; Filleron, T.; Gal, J.; Gauthier, M.; Le Deley, M. C.; Le Tourneau, C.; Medioni, J.; Nguyen, J. M.; Chabaud, S.; Teixeira, L.; Thivat, E.; You, B.; Kramar, A.; Paoletti, X. |